Tilray Brands, Inc. (NASDAQ:TLRY) Receives $13.33 Consensus PT from Brokerages

Shares of Tilray Brands, Inc. (NASDAQ:TLRY) have been given a consensus recommendation of “Hold” by the eight analysts that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and one has given a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $13.3333.

Several research firms have recently issued reports on TLRY. Zacks Research raised shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 11th. Roth Mkm lowered their price target on Tilray Brands from $20.00 to $10.00 and set a “neutral” rating on the stock in a report on Tuesday, January 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tilray Brands in a report on Wednesday, January 21st. Wall Street Zen lowered Tilray Brands from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Finally, ATB Cormark Capital Markets upgraded shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 10th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Hilton Head Capital Partners LLC purchased a new stake in shares of Tilray Brands in the 4th quarter worth approximately $38,000. Schonfeld Strategic Advisors LLC increased its holdings in shares of Tilray Brands by 4.5% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 144,358 shares of the company’s stock worth $1,304,000 after purchasing an additional 6,182 shares in the last quarter. IFP Advisors Inc raised its stake in shares of Tilray Brands by 14.3% in the fourth quarter. IFP Advisors Inc now owns 60,318 shares of the company’s stock worth $545,000 after purchasing an additional 7,541 shares during the last quarter. Integrated Wealth Concepts LLC lifted its holdings in shares of Tilray Brands by 33.8% during the third quarter. Integrated Wealth Concepts LLC now owns 36,977 shares of the company’s stock valued at $64,000 after purchasing an additional 9,341 shares in the last quarter. Finally, CreativeOne Wealth LLC boosted its position in shares of Tilray Brands by 12.2% during the third quarter. CreativeOne Wealth LLC now owns 87,134 shares of the company’s stock valued at $151,000 after buying an additional 9,452 shares during the last quarter. Hedge funds and other institutional investors own 9.35% of the company’s stock.

Key Tilray Brands News

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Tilray entered an asset purchase agreement to acquire key U.S. BrewDog assets — including the Columbus, Ohio brewery, a branded hotel, several pubs (Ohio, Las Vegas, Denver) and an airport location — expanding its U.S. craft-beer footprint and consumer-facing distribution. Tilray Brands Enters Agreement to Acquire BrewDog’s Key U.S. Assets
• Positive Sentiment: A sell-side upgrade framed Tilray’s larger “big bet on beverages” as a catalyst — analysts are now reframing the company as a consumer packaged-goods and beverage play, which can drive multiple re-rating if execution and margin mix improve. Tilray: Big Bet On Beverages (Rating Upgrade)
• Neutral Sentiment: Local-market acceptance may smooth integration: coverage notes BrewDog’s strong following in Ohio and that Tilray already sells cannabis-infused drinks, which could create cross‑sell or experiential opportunities at the acquired pubs. BrewDog’s US operations sold to new owner. What does that mean for Ohio?
• Neutral Sentiment: Commentary pieces highlight that Tilray’s diversification into beverages is strategic but long‑term; benefits depend on integration, brand management and margin expansion rather than immediate EPS upside. Will Tilray Brands’ Diversification Strategy Pay Off for Investors?
• Negative Sentiment: Deal economics were undisclosed and BrewDog has been described as a struggling seller — that raises short-term execution risk, potential capital outlay, and integration costs; Tilray remains unprofitable on margins and below its 50/200-day technical averages, which tempers upside. Tilray Quenches Thirst For U.S. Beer Assets With BrewDog Deal

Tilray Brands Price Performance

Shares of NASDAQ:TLRY opened at $6.95 on Wednesday. The company has a quick ratio of 1.72, a current ratio of 2.81 and a debt-to-equity ratio of 0.19. The stock’s 50 day moving average is $7.98 and its 200-day moving average is $10.65. Tilray Brands has a twelve month low of $3.51 and a twelve month high of $23.20. The firm has a market capitalization of $809.74 million, a price-to-earnings ratio of -0.31 and a beta of 1.96.

Tilray Brands (NASDAQ:TLRY) last announced its earnings results on Thursday, January 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.12. The company had revenue of $217.51 million for the quarter, compared to analysts’ expectations of $211.15 million. Tilray Brands had a negative return on equity of 6.35% and a negative net margin of 251.69%.During the same quarter in the previous year, the firm earned ($0.03) earnings per share. Sell-side analysts forecast that Tilray Brands will post -0.2 EPS for the current fiscal year.

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.